Breast Cancers Today Videos
HER3-DXd shows promise for CNS metastases in breast and lung cancer in the TUXEDO-3 trial, including patients with LMD. Sacituzumab + pembrolizumab improved PFS vs chemo in PD-L1+ TNBC in ASCENT-04, with no new safety signals.
Vepdegestrant improves PFS in ESR1-mutant ER+/HER2- breast cancer, offering a well-tolerated oral option post-CDK4/6. Dr. Lustberg discusses DESTINY-Breast09 and the potential shift to T-DXd + pertuzumab in HER2+ mBC first-line treatment. Stephanie Graff, MD, reviews top ASCO25 breast cancer trials, including ASCENT-04, DESTINY-Breast09, and SERENA-6.
Dr. Gradishar discusses how tolerability, toxicity, and NCCN guidelines shape HER2+ breast cancer treatment decisions.
Dr. William Gradishar discusses treatment sequencing strategies for HER2+ metastatic breast cancer at ASCO 2025. Dr. Eva Blondeaux discusses RRSO timing and fertility in young BRCA+ women and the need for shared, personalized decisions.
Risk-reducing surgery improves survival in young BRCA1/2 carriers, study shows, guiding counseling for high-risk patients. PALMIRA trial shows limited benefit of palbociclib rechallenge in HR+/HER2- breast cancer, guiding future treatment choices. New staging model links treatment response to survival, refining breast cancer prognosis after neoadjuvant chemotherapy. A new AJCC model refines breast cancer staging after neoadjuvant chemo, filling a key gap in patient prognostication. Dr. Soliman explores dendritic cell vaccines to boost immunity and cut chemo toxicity in early HER2-positive breast cancer. Pilot study shows HER2-targeted dendritic cell vaccines may enhance immune response in early HER2-positive breast cancer. Dr. Nunnery weighs IV Enhertu vs oral chemo, highlighting how patient goals and QoL shape treatment decisions. Dr. Nunnery discusses HER2-low and ultralow testing and Enhertu’s role after DESTINY-Breast06 in metastatic breast cancer. Dr. Sadie Dobrozsi spoke on the importance of genetic testing in breast cancer to better understand the disease. Dr. Leah Pyter details a study which found that chemotherapy induces microbiome disruption and inflammation in BC patients. Dr. Mik Rinne discusses a study on the efficacy of the CDK2 inhibitor BLU-222 in patients with HR+/HER2- breast cancer. Carlos Doti, MD, of AstraZeneca, discusses the impact of LYNPARZA over the last decade.